Coverage
Filings
Danish biosolutions company Novonesis on Thursday raised its full-year sales forecast after reporting strong growth for the first nine months of the year, citing a robust performance across its markets.
Novonesis on Wednesday laid out new long-term financial targets, aiming to accelerate sales growth and expand profit margins through 2030 as part of its new ‘GROW’ strategy.
Novonesis has successfully completed its acquisition of dsm-firmenich's share of the Feed Enzyme Alliance, the company announced.
| 8 Apr 2024 |
| Invitation to the annual shareholders' meeting | 8 Apr 2024 |
| 2024 outlook and pro forma financials | 21 Mar 2024 |
| Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 | 18 Mar 2024 |
| Resolutions from the Extraordinary Shareholders' Meeting 2024 | 4 Mar 2024 |